Another GLP-1 receptor agonist in clinical application is Exenatide, which yields better improvement in the noninvasive Fibrosis 4 index and greater benefit in terms of body weight and liver enzymes than insulin Glargine in NAFLD patients with type 2 diabetes (NCT02303730) (40). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.